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Abstract
Chronic pulmonary infection with P. aeruginosa develops in most patients with cystic ﬁbrosis (CF); by adulthood 80% of patients are
infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF. Chronic infection is preceded by
an intermittent stage of infection. The initial stage is characteristically followed by the gradual emergence of mucoid variants of the colonizing
strains and a rise in anti-Pseudomonas antibodies. In addition to optimizing existing therapeutic strategies, effective new agents need to be
identiﬁed. Studies in patients with CF are particularly challenging: the progressive nature of the disease and the wide variation in severity
inﬂuence considerably the outcome of drug testing. A validated, universally accepted, and clinically useful classiﬁcation of patients infected
with P. aeruginosa, particularly those chronically infected, is needed that can be used as both a criterion for patient selection for clinical trials
and as a study endpoint.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Improvements in clinical care have resulted in a dramatic
increase in the life expectancy of patients with cystic ﬁ-
brosis (CF) over the last 40 years [1]. In several European
countries, the median survival is now between 30 and 40
years. The aggressive treatment of lung disease and im-
provements in nutrition are the major factors responsible.
However, 95% of people with CF still die from respiratory
failure. Pseudomonas aeruginosa (P. aeruginosa) is the most
common pathogen causing chronic infection in people with
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CF. Chronic pulmonary infection with P. aeruginosa develops
in most patients with CF; by adulthood 80% of patients are
infected in most CF centres and chronic P. aeruginosa infec-
tion is the primary cause of increased morbidity and mortality
in CF [2–11]. In addition to optimising existing therapeutic
strategies, effective new agents need to be identiﬁed. Studies
in patients with CF are particularly challenging because of
the progressive nature of the disease and the wide variation
in severity and number of organs involved, which inﬂuences
considerably the outcome of drug testing. Confounding fac-
tors for which patients may be stratiﬁed include their class of
mutation, age, gender, bacterial lung infection, lung function,
pancreatic function, hepato-biliary disease and nutritional sta-
tus. The most relevant and robust endpoint for interventional
studies in CF patients is survival. However, the use of survival
as an endpoint is no longer appropriate as it would take
enormous numbers of patients and many years to see an
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effect. Thus, surrogate endpoints and biomarkers are needed.
One such endpoint is the prevalence of chronic P. aeruginosa.
A validated, universally accepted, and clinically useful clas-
siﬁcation of patients infected with P. aeruginosa, particularly
those chronically infected, is needed that can be used as both
a criterion for patient selection for clinical trials and as a
study endpoint. For studies evaluating different treatments for
chronically infected patient populations, the proper deﬁnition
of chronic infection is crucial for the interpretation of results,
as well as when assessing different isolation policies. Without
a universally accepted deﬁnition of chronic P. aeruginosa in-
fection comparison of results from different CF centres or the
clinical effectiveness of different anti-Pseudomonas strategies
will not be possible.
2. Deﬁnition of chronic P. aeruginosa infection
Currently there is no universally accepted deﬁnition of
chronic P. aeruginosa infection. Most of the currently used
deﬁnitions are based on microbiological results from sputum
cultures. However, modern CF care, particularly the success
of early P. aeruginosa eradication protocols, makes the
microbiological deﬁnition less appropriate. Moreover, the
accuracy of any deﬁnition using culture results will depend
on the frequency of microbiological assessment of secretions
from the respiratory tract of CF patients.
Chronic infection can be deﬁned as an infection, which
persists in spite of therapy, and in spite of the host’s immune
and inﬂammatory response. Moreover, in contrast to bacterial
colonization, chronic infection is characterized by persistent
pathology and immune responses. This deﬁnition of chronic
infection necessitates the measurement of immune responses,
the measurement of speciﬁc anti-Pseudomonas antibodies.
The following deﬁnitions of chronic P. aeruginosa infec-
tion in CF have been published and used either in clinical
settings or for research purposes:
1. The Copenhagen deﬁnition of chronic P. aeruginosa infec-
tion [2] was formulated as:
• Persistent presence of P. aeruginosa for at least 6
consecutive months, or less when combined with the
presence of two or more P. aeruginosa precipitating
antibodies and
• Intermittent P. aeruginosa colonization was deﬁned as a
culture of P. aeruginosa at least once and the presence
of normal levels of precipitating antibodies against
P. aeruginosa.
All patients were controlled on a regular monthly basis and
each patient had an average of 10 sputum cultures per year.
2. The steps in the course of P. aeruginosa colonization were
deﬁned by Ballmann et al. [11] as:
• ﬁrst detection of P. aeruginosa (PA1),
• chronic P. aeruginosa colonization (PAc),
• ﬁrst detection of mucoid P. aeruginosa strains (PAm),
and
• chronic mucoid P. aeruginosa colonisation (Pacm).
For transition to the chronic stages (PAc and PAcm) more
than 50% of cultures in a 12 month period had to be positive
for P. aeruginosa and the related phenotype (mucoid or
non-mucoid).
Patients were seen regularly one to four times a year.
At each visit a sputum sample or a deep throat swab was
collected.
3. In 2003, Lee et al. [12] formulated the Leeds deﬁnition of
different stages of P. aeruginosa infection and colonization
as:
• Chronic infection: When more than 50% of months,
when samples had been taken, were P. aeruginosa
culture positive.
• Intermittent infection: When 50% or less of months,
when samples had been taken, were P. aeruginosa
culture positive.
• Free of infection: No growth of P. aeruginosa during
the previous twelve months, having previously been
P. aeruginosa culture positive.
• Never infected: P. aeruginosa never cultured from
sputum or cough swab.
The recommendation for sampling of sputum or cough
swabs is at least every three months. The mean number of
samples taken is between 7 and 10 per year.
4. In 2006, Proesmans et al. [13] evaluated the deﬁnition of
Lee et al. [12] (Leeds criteria) for chronic P. aeruginosa
infection in the paediatric and adult CF populations at the
CF centre in Leuven, Belgium. The proﬁle of patients with
different stages of P. aeruginosa infection and colonization
were compared with clinical and biochemical parameters.
In addition, the levels of P. aeruginosa antibodies in the
four groups were measured.
No differences in P. aeruginosa antibody levels were found
between the intermittent infection and free of infection groups.
The authors conﬁrmed the agreement between P. aeruginosa
status according to the Leeds deﬁnition and both clinical
status and levels of P. aeruginosa antibodies. At least 4 airway
cultures were required in different months spread over the
year.
5. The publications of Pressler et al. [14,15] demonstrated the
potential diagnostic value of speciﬁc antibody measure-
ments as a prognostic tool to identify CF patients at risk of
establishing chronic P. aeruginosa infection.
On average, sputum culture covered 10 months per year
(range 4–12).
6. Ratjen et al. [16] evaluated the usefulness of speciﬁc serum
antibodies in deﬁning the status of P. aeruginosa infection
as well as the response to early intervention treatment in
CF patients. Serum antibody titers were on average low at
the time of ﬁrst P. aeruginosa isolation from respiratory
specimens and they decreased during treatment. The data
of Ratjen et al. [16] suggest that serum antibody titers
might be used to monitor the response of CF patients to
therapy because they detect the presence of P. aeruginosa
in respiratory cultures of CF patients with high sensitivity
and speciﬁcity.
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3. Availability and limitations
1. The accuracy of any deﬁnition will depend on the fre-
quency of sampling. Different numbers of sputum cultures
have been used and recommended by different authors.
The UK Cystic Fibrosis Trust suggests sampling sputum
at least every 2 months (six times per year) in children
and every 3 months (four times per year) in adults [17]. In
Ballmann et al. [11], patients were seen regularly one to
four times a year, while in Copenhagen, sputum is cultured
on average 10 times per year from each patient (once per
month) [14]. Both Proesmans et al. [13] and Lee et al. [12]
recommended that sputum or cough swabs should be taken
at least every three months (four times per year), but the
mean number of samples taken was between 7 and 10 per
year.
2. Acquisition of P. aeruginosa can occur at an early age,
but may remain undetected depending on the frequency
of airway sampling and the site where the sample is
taken. Diagnosis of P. aeruginosa acquisition is based on
sputum microbial culture or is replaced by cough swabs
for patients, mainly young children, unable to expectorate
sputum. The negative predictive value of a cough swab
for P. aeruginosa is known to be as high as 95% with a
low positive predictive value of only 44% [18]. Speciﬁc
P. aeruginosa IgG values have a high sensitivity (88–97%)
and speciﬁcity (83–96%) measured by different assays to
distinguish chronically infected patients from the rest of
the cohort. Positive predictive value varies between 80%
and 92.1% and negative predictive value at 93.9–95%
[13,15].
4. Can chronic P. aeruginosa infection be used as an
outcome measurement in clinical studies?
The introduction of cohort isolation and early intensive
treatment following the initial isolation of P. aeruginosa
resulted in a reduced incidence and prevalence of chronic
P. aeruginosa infection [5,19–21].
Furthermore, the time from acquisition of ﬁrst P. aerug-
inosa to development of chronic P. aeruginosa infection
increased signiﬁcantly, from approximately 1 year to almost
4 years after introduction of cohort isolation [5]. After intro-
duction of early intensive treatment, the probability of still
not having developed chronic P. aeruginosa infection 15 years
after the ﬁrst isolation of P. aeruginosa was above 80% [22].
Management strategies reported by other CF centres were also
associated with both reduced prevalence and an increase in
the mean age of onset of chronic P. aeruginosa infection [19].
The yearly prevalence of patients having chronic P. aerugi-
nosa infection fell signiﬁcantly during the study period from
24.5% in 1990 to 18.1% in 2000 (p < 0.05), despite an
increase in mean age of CF patients from 7.7 to 9.4 years. The
number of patients aged less than 11 years who had chronic
P. aeruginosa infection fell from 23.8% in January 1990 to
only 4.3% by December 2000 [19].
For over 15 years, strict segregation of patients on a
bacteriological basis and early, often “prophylactic” use of
inhaled antibiotics have been progressively implemented to
treat P. aeruginosa infection. At the end of 2003, 94.4% of
patients aged younger than 18 years were on intermittent or
continuous inhaled antibiotic therapy and the prevalence of
P. aeruginosa among 116 patients was 20.7%. The chronic
colonization rate was 19.8%, but only 2.8% in patients aged
less than 18 years (n = 72). Serologic data strongly support
these results [20].
5. Do we have surrogate markers of chronic P. aeruginosa
infections in CF?
As anti-Pseudomonas management strategies are associ-
ated with both reduced prevalence and an increase in the
mean age of onset of chronic P. aeruginosa infection, there
is need of surrogate markers for study end-points [5,19,23].
The mucoid phenotype and increasing levels of speciﬁc anti-
Pseudomonas antibodies are risk factors for the development
of chronic P. aeruginosa infection. Mucoid P. aeruginosa
plays a much greater role in CF lung disease progression than
non-mucoid P. aeruginosa [3,14].
The greatest risk factor for development of chronic
P. aeruginosa infection is increasing levels of speciﬁc anti-
Pseudomonas IgG antibodies 3 years prior to the onset of
chronic infection, with odds 7.4, (p < 0.005), and growth of
mucoid P. aeruginosa strains with OR of 7.4, p = 0.006) [14].
Regular determination of serum antibodies has been re-
ported to be useful in CF patients intermittently infected and
free of infection by P. aeruginosa [13–15,24]. Longitudinal
assessment of antibody titers assessed before and after inhaled
antibiotic therapy in patients with ﬁrst P. aeruginosa isola-
tion showed a signiﬁcant decrease in antibody titers against
P. aeruginosa antigens in patients clearing P. aeruginosa in-
fection, whereas titers increased in patients in whom antibiotic
therapy failed to eradicate the organism [16].
6. Conclusions and recommendations from the chronic
P. aeruginosa infection deﬁnition Working Group
Because the deﬁnition of infection is based on results
from microbiological investigations of sputum or cough swab
samples, the results will depend on the number of investigated
samples. We therefore recommend that over the course of
one year either (i) a minimum of 6 samples – if sputum –
in separate months should be examined or (ii) a minimum of
8 samples in separate months should be examined – if other
samples (cough swab, nasopharyngeal aspirate) are used. The
negative predictive value of cough swab is reported to be
95% [18]. The deﬁnition of chronic P. aeruginosa infection
is proposed to be deﬁned as 50% or more of these samples
being positive in the preceding 12 months. This deﬁnition can
be useful as an entry criterion in studies where chronically
infected patients are a target group. As the sensitivity and
positive predictive value of cultures from respiratory tract
secretions are poor [18], the deﬁnition of intermittently
colonised CF patients should be based on both culture results
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and levels of anti-Pseudomonas antibodies below the deﬁned
chronic infection cut-off level (taken within the last three
months). There are only two commercially available assays
for the detection of anti-Pseudomonas antibodies [14,16] as
well as a number of other tests used in one or a few CF
centres. There is therefore a need to evaluate and compare
the assays used by the majority of CF centres to detect anti-
Pseudomonas antibodies. In the future, the establishment of a
reference laboratory to evaluate assays for anti-Pseudomonas
antibodies might be a solution.
The group of CF patients who are always negative for
P. aeruginosa infection are extremely interesting. However,
the deﬁnition of this group of CF patients is problematic.
One deﬁnition proposed is: Patients must have documented at
least 6 sputum or 8 cough swab samples per year negative for
P. aeruginosa and this for all years since diagnosis, together
with level of speciﬁc anti-Pseudomonas antibodies below the
deﬁned cut-off level.
7. Recommendation of Endpoints for studies
1. Chronic infection with P. aeruginosa (as deﬁned above)
can be used as an endpoint in future clinical trials.
2. to next positive sample for P. aeruginosa can represent a
useful additional endpoint.
3. Speciﬁc anti-Pseudomonas antibodies can provide a sur-
rogate marker for infection, but needs further evaluation
before being used as a trial endpoint.
4. Using mucoid/non-mucoid phenotype as an endpoint in
clinical studies cannot be recommended at the present time
because of the need to standardise methodology.
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